Jade Art Group Announces Conference Call for the Five Month Transitional Period Ended December 31, 2007

Wednesday March 26 6:44 AM

Conference Call Details

Interested participants should dial 877-269-7756 when calling within the United States or 201-689-7817 when calling internationally. Please register for the conference call 10 minutes before the scheduled start time. There will be a playback available until April 10, 2008. To listen to the playback dial 877-660-6853 when calling within the United States, or 201-612-7415 when calling internationally and use replay ID number 279666.

This conference call is also available via webcast and can be accessed by visiting Jade Art Group's website: www.jadeartgroupinc.com/investorrelations.asp

About Jade Art Group Inc.

Jade Art Group Inc., through its wholly owned subsidiary, Jiangxi SheTai Jade Industrial Co., Ltd., sells and distributes raw jade ranging in uses from decorative construction material to high-end jewelry sourced from the SheTai Jade mine in China. This mine has one of the largest jade reserves in China and is owned by XiKai, with which Jade Art Group signed an agreement to acquire exclusive distribution rights to sell 90% of the SheTai Jade produced from the mine for the next 50 years. Several national jade experts have noted the perceived superiority of SheTai Jade as compared to the other existing varieties of Chinese jade.

For more information, please visit: www.jadeartgroupinc.com

Contact:

Jade Art Group Inc.
Kevin McEnery, 646-200-6302
Managing Director - Finance
kevin@jadeartgroupinc.com
or
Wanru Zhao, 646-200-6328
Vice President
wzhao@jadeartgroupinc.com
or
Winning IR Company, Ltd.
Darren Minton, 212-823-0523
darren.minton@winningir.com

Related Quotes

Finance Message Boards Most recent posts: Charting China 514 I am selling 800,000 FRV shares now 8 Rare Earth Elements - Part 2 118 WESTPAC RAISES INTEREST RATES - GOOD! 108 October 2010 predictions 76 More Finance Boards

Email this story -   Printer friendly version

Next article:	Research and Markets: New Report Assesses the Prospects for Sugar Substitute Stevioside in China
Previous article:	Get a Guide to Pharmaceutical Outsourcing in China